Buybacks have gotten a bad rap from both Republicans and Democrats. But stocks would be trading at a massive discount without them.Marketsread more
The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
Stocks rose on Friday, but notched weekly losses as investors worried the U.S.-China trade war is hurting economic growth.US Marketsread more
The combination of mounting recession fears, bets on a more cautious Fed and a regular uptick in market volatility could spell more losses.Marketsread more
The therapy, Zolgensma, is a one-time treatment for spinal muscular atrophy — a muscle-wasting disease and leading genetic cause of infant mortality, affecting 1 in every...Biotech and Pharmaceuticalsread more
SpaceX has raised just over $1 billion in financing since the beginning of the year.Investing in Spaceread more
An analyst for Ark Invest, which has a major investment in Tesla, says recent drastic price-target cuts by others on Wall Street are missing the big picture.Investingread more
A federal judge in California has blocked President Donald Trump from building sections of his long-sought border wall with money secured under his declaration of a national...Politicsread more
Former Foreign Minister Boris Johnson is seen as the bookmaker's favorite to succeed outgoing Prime Minister Theresa May.Europe Politicsread more
The race is underway to find a vaccine that can control African swine fever, a highly contagious and deadly viral infection ravaging China's hog population. There is currently...Agricultureread more
Inovio Pharmaceuticals' Zika vaccine will be the 14th drug the company has in testing, but its CEO insisted Tuesday the company is not spread too thin and is ready to take on its larger rivals.
Inovio announced Monday its experimental vaccine for the Zika virus received approval from U.S. regulators for an early-stage human trial testing.
"Our pipeline is very full and very productive. We're able to advance a lot of products," president and CEO Joseph Kim said in an interview with "Power Lunch " on Tuesday. "We can rapidly and safely move these programs forward."
The early-stage Zika study will enroll 40 healthy subjects and evaluate safety, tolerability and immune response to the vaccine.
The World Health Organization declared Zika a global health emergency. The illness has been associated with microcephaly, a birth defect characterized by an usually small head and potential developmental problems.
Inovio also has an Ebola vaccine in the pipeline and is competing against the likes of Merck, Johnson & Johnson and GlaxoSmithKline. However, Kim is confident his company can take on its larger rivals.
"We're fortunate enough to have a technology and DNA-based therapies where we can safely and perhaps more efficiently and effectively advance these products," he said.
Meanwhile, its "leading product" for cervical dysplasia is about to enter phase-three studies, said Kim. He downplayed the two-year gap between the drug's phase-two and phase-three studies.
"It takes a long time to take new disruptive technologies for these important diseases forward," he explained.
— Reuters contributed to this report.